Frontlight ResearchEarly access
Taking people in United StatesNo phase
A registry following adults with obesity who are treated by obesity specialists
Follows adults with excess weight or obesity under specialist care over time.
Key facts
- Who runs it
- CorEvitas
- Where
- Waltham, United StatesSee the site
- Trial code
- Registry title
- PPDTM CorEvitasTM Obesity (OBR) Drug Effectiveness and Safety Registry
- Status
- Recruiting
- People taking part
- 10,000 people, planned
- Started
- 29 Oct 2025
- Expected to end
- 31 Dec 2099
- Type of study
- Observational
- Treatments tested
- Biospecimen collection
- Record updated
- 27 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults living with excess weight or obesity. They must be treated by a doctor who has experience with obesity.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Excess weight or obesity.
- Earlier treatment
- A doctor must see the person as a good candidate for a commercially available obesity medication. If a GLP-based or non-GLP-based obesity medication is prescribed, the person must be starting it for the first time.
Main reasons for not taking part
- Has Type 2 diabetes (T2D)
- Is in, or plans to join, a blinded clinical trial
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- To be eligible to participate in this registry, an individual must meet all of the following criteria:
- In the opinion of the investigator, the subject is considered a suitable candidate for treatment with a commercially available systemic obesity medication (see Enrollment Eligible Treatments). While subjects do not need to start an obesity medication at the time of registry enrollment, those prescribed a GLP-based or non-GLP-based obesity medication must be initiating the medication for the first time
- Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable laws of the jurisdiction in which the research is being conducted at the time of enrollment
- Is willing and able to consent to participation in the registry
- Is willing and able to complete registry-related forms electronically via personal devices
- Is willing and able to provide first name, last name, email address, language, and primary time zone for electronic data collection account creation
- For US subjects only, is willing and able to provide Personally Identifiable Information which includes full legal name, sex at birth, date of birth, and home address zip code
Who cannot take part
- Has Type 2 diabetes (T2D)
- An individual who meets any of the following criteria will be excluded from participation in the registry:
- Is participating or planning to participate in a blinded clinical trial
Where in United States
- CorEvitas, LLCWaltham, United StatesContact: Regulatory CorevitasTaking people
About the trial
What the trial wants to find out
The design is an open-ended prospective observational (non-interventional) registry for subjects living with excess weight or obesity under the care of a qualified provider with documented experience treating patients with obesity
Treatments tested
- Biospecimen collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- PPDTM CorEvitasTM Obesity (OBR) Drug Effectiveness and Safety Registry
- Plain-language title
- A registry following adults with obesity who are treated by obesity specialistsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 27 August 2026